Oral VEGFR inhibitors and erlotinib in EGFR wild type NSCLC patients
| Author | Phase | Line of Treatment | Patients | Treatment | Response rate (%) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|---|
| Spigel et al. [29] | II | Second line | 168 | Sorafenib + erlotinib vs. placebo + erlotinib | 8 vs. 11, P = 0.555 | 3.38 vs. 1.94, HR: 0.86; 95% CI: 0.60-1.22 P = 0.196 | 7.62 vs. 7.23, HR: 0.89; 95% CI: 0.59-1.34 P = 0.290 |
| Scagliotti et al. [32] | III | Second line | 960 | Sunitinib + erlotinib vs. placebo + erlotinib | 10.6 vs. 6.9, P = 0.0471 | 3.6 vs. 2.0 HR: 0.807; 95% CI: 0.695-0.937 P = 0.0023 | 9.0 vs. 8.5, HR: 0.922; 95% CI: 0.797-1.067 P = 0.1388 |
| Groen et al. [33] | II | Second line | 132 | Sunitinib + erlotinib vs. placebo + erlotinib | 4.6 vs. 3.0, P = 0.624 | 2.8 vs. 2.0 HR: 0.898; 80% CI: 0.671-1.203 P = 0.321 | 8.2 vs. 7.6 HR: 1.066; 95% CI: 0.705-1.612 P = 0.617 |